PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)

Gerald F. Watts, Dick C. Chan, Jing Pang, Louis Ma, Qidi Ying, Shashi Aggarwal, Santica M. Marcovina, P. Hugh R. Barrett

Research output: Contribution to journalArticlepeer-review

23 Citations (Web of Science)

Fingerprint

Dive into the research topics of 'PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry